帕夫骨化醇 | 381212-03-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 帕夫骨化醇
• 英文名称: 2-((S)-1-{(S)-4-[2-[(3S,5R)-3,5-dihydroxy-2-methylene-cyclohex-(Z)-ylidene]eth-(E)-ylidene]-7a-methyl-3a,4,5,6,7,7a-hexahydro-3H-inden-1-yl}ethoxy)-N-(2,2,3,3,3-pentafluoropropyl)acetamide
• 英文别名: M518101；{(1α,3β-dihydroxy-9,10-secopregna-5,7,10(19),16-tetraen-20(S)-yl)oxy}-N-(2,2,3,3,3-pentafluoropropyl)acetamide；[{(5Z,7E)-(1S,3R,20S)-1,3-dihydroxy-9,10-secopregna-5,7,10(19),16-tetraen-20-yl}oxy]-N-(2,2,3,3,3-pentafluoropropyl)acetamide；Pefcalcitol；2-[(1S)-1-[(3aS,4E,7aS)-4-[(2Z)-2-[(3S,5R)-3,5-dihydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-3a,5,6,7-tetrahydro-3H-inden-1-yl]ethoxy]-N-(2,2,3,3,3-pentafluoropropyl)acetamide
• CAS: 381212-03-9
• 化学式: C₂₆H₃₄F₅NO₄
• 分子量: 519.552
• InChiKey: SVCSMAZYWOQCBW-NVJMFHFGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  36
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  78.8
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  [{1α,3β-bis(tert-butyldimethylsilyloxy)-9,10-secopregna-5,7,10(19),16-tetraen-20(S)-yl}oxy]-N-(2,2,3,3,3-pentafluoropropyl)acetamide 以76.7的产率得到帕夫骨化醇
  参考文献：
  名称：

  Process for producing vitamin D derivative using convergent method

  摘要：

  提供了一种新的生产[{(5Z,7E)-(1S,3R,20S)-1,3-二羟基-9,10-去氢孕酮-5,7,10(19),16-四烯-20-基}氧基]-N-(2,2,3,3,3-五氟丙基)乙酰胺的方法，该方法如下反应方案所示：一种用于实施该方法的中间体，以及生产该中间体的方法。

  公开号：

  US08173824B2

文献信息

• Vitamin d derivatives
  申请人：——

  公开号：US20040019023A1

  公开（公告）日：2004-01-29

  The object of the present invention is to provide vitamin D derivatives that have excellent physiological activities as medicines, particularly as therapeutic agents for skin diseases such as psoriasis, and that have a reduced hypercalcemic effect. The present invention provides a vitamin D derivative of Formula (1): 1 wherein X represents an oxygen atom or a sulfur atom; m represents a number of 1 to 3; R 1 and R 2 each represent a hydrogen atom or an alkyl group; R 4 and R 5 each represent a hydrogen atom or a hydroxyl group, etc.; R 3 represents —YR 8 , etc.; R 6 represents a hydrogen atom, etc.; and R 7 represents a hydrogen atom, etc.

  本发明的目的是提供作为药物的维生素D衍生物，特别是作为治疗银屑病等皮肤疾病的治疗剂，并且具有减少高钙血症作用的维生素D衍生物。 本发明提供了化学式（1）的维生素D衍生物： 1 其中 X代表氧原子或硫原子； m代表1至3的数字； R 1 和R 2 分别代表氢原子或烷基； R 4 和R 5 分别代表氢原子或羟基等； R 3 代表—YR 8 等； R 6 代表氢原子等；以及 R 7 代表氢原子等。
• PROCESS FOR PRODUCING VITAMIN D DERIVATIVE USING PHOTOREACTION
  申请人：Kawase Akira

  公开号：US20100261917A1

  公开（公告）日：2010-10-14

  There are provided a novel process for producing [(5Z,7E)-(1S,3R,20S)-1,3-dihydroxy-9,10-secopregna-5,7,10(19),16-tetraen-20-yl}oxy]-N-(2,2,3,3,3-pentafluoropropyl)acetamide, which process is characterized by irradiating a compound represented by the formula: with UV to ring-open the compound, and then isomerizing the resulting compound; an intermediate useful for carrying out the process; and a process for producing the intermediate.

  提供了一种新的生产[(5Z,7E)-(1S,3R,20S)-1,3-二羟基-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二氢-9,10-二
• PROCESS FOR PRODUCING VITAMIN D DERIVATIVE USING CONVERGENT METHOD
  申请人：Ogasawara Kunio

  公开号：US20100217020A1

  公开（公告）日：2010-08-26

  There are provided a novel process for producing [(5Z,7E)-(1S,3R,20S)-1,3-dihydroxy-9,10-secopregna-5,7,10(19),16-tetraen-20-yl}oxy]-N-(2,2,3,3,3-pentafluoropropyl)acetamide, which process is shown in the following reaction scheme: an intermediate useful for carrying out the process, and a process for producing the intermediate.

  提供了一种新的生产过程，用于生产[(5Z,7E)-(1S,3R,20S)-1,3-二羟基-9,10-secopregna-5,7,10(19),16-四烯-20-基}氧基]-N-(2,2,3,3,3-五氟丙基)乙酰胺，该过程如下反应方程所示：生产该中间体的有用方法和生产该中间体的过程。
• METHOD FOR PRODUCING VITAMIN D DERIVATIVE BY USING CONVERGENT METHOD
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：EP1955999A1

  公开（公告）日：2008-08-13

  There are provided a novel process for producing [(5Z,7E)-(1S,3R,20S)-1,3-dihydroxy-9,10-secopregna-5,7,10(19),16-tetraen-20-yl}oxy]-N-(2,2,3,3,3-pentafluoropropyl)acetamide, which process is shown in the following reaction scheme: an intermediate useful for carrying out the process, and a process for producing the intermediate.

  提供了一种生产[(5Z,7E)-(1S,3R,20S)-1,3-二羟基-9,10-仲孕酮-5,7,10(19),16-四烯-20-基}氧基]-N-(2,2,3,3,3-五氟丙基)乙酰胺的新工艺，该工艺的反应方案如下： 一种用于实施该工艺的中间体，以及一种生产该中间体的工艺。
• EP1955999
  申请人：——

  公开号：——

  公开（公告）日：——